https://www.selleckchem.com/products/selonsertib-gs-4997.html This study aimed to examine the association of less-certain indication of chronic total occlusion percutaneous coronary intervention (CTO-PCI) with subsequent clinical outcomes. The impact of patient symptoms, myocardial viability, and clinical and anatomic risk on long-term outcomes is underdetermined. Consecutive patients undergoing CTO-PCI at a large-volume single center between 2010 and 2013 were included. Central adjudication was used to assess the appropriateness of three prespecified indications. The primary outcome was the 5-year composite endpoint of death or myocardial infarction (MI). Of 2,659 patients with 2,735 CTO lesions, the 348 (13.1%) asymptomatic patients, 164 (6.2%) patients without viable myocardium in the CTO territory, and 306 (11.5%) patients in whom the Synergy between PCI with Taxus and Cardiac Surgery Score II favored coronary artery bypass grafting (CABG) had higher 5-year death or MI compared with the rest patients in each category (12.0% vs. 8.6%, p = .04; 16.3% vs. 8.5%, p < .0001; 12.2% vs. 8.6%, p = .03), respectively. Multivariable regression analysis demonstrated that without symptom (hazard ratio 1.51; 95% confidence interval 1.06-2.15; p = .02), non-viable myocardium in CTO territory (hazard ratio 1.77; 95% confidence interval 1.16-2.72; p = .009), and deemed more favorable for CABG (hazard ratio1.54; 95% confidence interval 1.04-2.28; p = .03), but not the technical success (hazard ratio0.85; 95% confidence interval 0.62-1.18; p = .34), were independent predictors for the primary endpoint. In this large cohort of CTO-PCI, those who were asymptomatic, non-viable myocardium in the CTO territory, or deemed more favorable for CABG were associated with higher risk of long-term mortality or MI. In this large cohort of CTO-PCI, those who were asymptomatic, non-viable myocardium in the CTO territory, or deemed more favorable for CABG were associated with higher risk of long-t